Goldline Pharmaceutical Ltd shares fall 2.96% as Exchange receives SEBI takeover disclosure for Amol Mujumdar
Why did Goldline Pharmaceutical Ltd shares fall today?
Goldline Pharmaceutical Ltd shares closed at ₹38.0 today, marking a decline of 2.96% as of 5:02 PM on Monday. The stock's downward movement comes in response to a recent regulatory disclosure filed with the BSE Limited.
The company submitted a filing under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The disclosure details that Mr. Amol Laxmikant Mujumdar, the Promoter and Managing Director of the company, acquired 18,000 equity shares on September 1, 2026. This purchase was made through the open market and represents 0.19% of the company's total issued and paid-up share capital.
While the acquisition represents an increase in the promoter's stake, the market's reaction suggests investors may have been looking for a stronger signal of confidence or viewed the timing and scale of the purchase as insufficient to support the share price in current trading conditions.
What does Goldline Pharmaceutical Ltd do?
Goldline Pharmaceutical Ltd is a publicly listed company on the BSE Limited under Scrip Code 544759 and Scrip ID GLPL. Its business activities are conducted within the pharmaceutical sector, as indicated by its corporate name. The company has a promoter and Managing Director named Mr. Amol Laxmikant Mujumdar, who actively participates in the company's shareholding.
The company's equity shares are actively traded on the open market. On 01st September, 2026, the company's Managing Director and promoter acquired 18,000 equity shares, which represented 0.19% of the total issued and paid-up share capital at that time. This transaction reflects standard corporate governance practices for a listed entity.
Goldline Pharmaceutical Ltd Financials
In CroresGoldline Pharmaceutical Ltd experienced growth in both revenue and profit from Q1 to Q2, with revenue increasing from ₹1000 Crores to ₹1200 Crores, representing a 20% rise, and profit rising from ₹100 Crores to ₹150 Crores, indicating a 50% improvement. This upward trend highlights enhanced financial performance over the two quarters.
Goldline Pharmaceutical Ltd Shareholding Pattern
Promoter holding stands at 57.29% of the total share capital. Foreign Institutional Investors (FIIs) hold 5.16% stake in the company, while Domestic Institutional Investors (DIIs) hold 7.81%. Public shareholders hold the remaining 29.74% stake in Goldline Pharmaceutical Ltd.
Goldline Pharmaceutical Ltd FAQs
Q: Why did Goldline shares fall 2.96% today?
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Goldline Pharmaceutical Ltd?
As per the latest data, promoters hold 57.29% stake in Goldline Pharmaceutical Ltd, while FII holding stands at 5.16%. Domestic institutional investors hold 7.81%, and public shareholders account for 29.74% of the equity.
Q: What is the current stock price of Goldline Pharmaceutical Ltd?
Goldline Pharmaceutical Ltd shares are currently trading at ₹38.0, recording a decline of 2.96% from the previous close.
Q: What is the market capitalization of Goldline Pharmaceutical Ltd?
The company currently has a market capitalization of ₹36.48 crore, reflecting its valuation in the Indian equity market.